1693P CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
Loading...
Contact
Check for full-text access
Issue Date
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
Background: We report final data from CaboPoint, a prospective study of second-line (2L) cabozantinib in aRCC after first-line (1L) standard of care CPI-based therapy.
Description
Citation
Publisher
License
Journal
Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO
Volume
Issue
13-17